U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C16H17N2O5S.K
Molecular Weight 388.48
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PENICILLIN V POTASSIUM

SMILES

[K+].[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)COC3=CC=CC=C3)C([O-])=O

InChI

InChIKey=HCTVWSOKIJULET-LQDWTQKMSA-M
InChI=1S/C16H18N2O5S.K/c1-16(2)12(15(21)22)18-13(20)11(14(18)24-16)17-10(19)8-23-9-6-4-3-5-7-9;/h3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22);/q;+1/p-1/t11-,12+,14-;/m1./s1

HIDE SMILES / InChI

Molecular Formula K
Molecular Weight 39.0983
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C16H17N2O5S
Molecular Weight 349.382
Charge -1
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/064071s006lbl.pdf

Penicillin V is a penicillin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms. The name "penicillin" can either refer to several variants of penicillin available, or to the group of antibiotics derived from the penicillins. Penicillin V has in vitro activity against gram-positive and gram-negative aerobic and anaerobic bacteria. The bactericidal activity of Penicillin V results from the inhibition of cell wall synthesis and is mediated through Penicillin V binding to penicillin binding proteins (PBPs). Penicillin V is stable against hydrolysis by a variety of beta-lactamases, including penicillinases, and cephalosporinases and extended spectrum beta-lactamases. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, Penicillin V inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that Penicillin V interferes with an autolysin inhibitor. Used for the treatment of mild to moderately severe infections (e.g. dental infection, infections in the heart, middle ear infections, rheumatic fever, scarlet fever, skin infections, upper and lower respiratory tract infections) due to microorganisms.

Originator

Curator's Comment: John C. Sheehan, a chemistry professor at Massachusetts Institute of Technology and a former chemist at Merck, synthesized phenoxymethylpenicillin, also known as penicillin V in 1957

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Q8XJ01
Gene ID: 990276.0
Gene Symbol: pbpA
Target Organism: Clostridium perfringens (strain 13 / Type A)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Penicillin V

Approved Use

Penicillin V potassium tablets and Penicillin V potassium for oral solution are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. The following infections will usually respond to adequate dosage of Penicillin V. Streptococcal infections (without bacteremia). Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. Pneumococcal infections. Mild to moderately severe infections of the respiratory tract. Staphylococcal infections—penicillin G-sensitive. Mild infections of the skin and soft tissues. Fusospirochetosis (Vincent's gingivitis and pharyngitis)—Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin.

Launch Date

1990
Curative
Penicillin V

Approved Use

Penicillin V potassium tablets and Penicillin V potassium for oral solution are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. The following infections will usually respond to adequate dosage of Penicillin V. Streptococcal infections (without bacteremia). Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. Pneumococcal infections. Mild to moderately severe infections of the respiratory tract. Staphylococcal infections—penicillin G-sensitive. Mild infections of the skin and soft tissues. Fusospirochetosis (Vincent's gingivitis and pharyngitis)—Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin.

Launch Date

1990
Curative
Penicillin V

Approved Use

Penicillin V potassium tablets and Penicillin V potassium for oral solution are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. The following infections will usually respond to adequate dosage of Penicillin V. Streptococcal infections (without bacteremia). Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. Pneumococcal infections. Mild to moderately severe infections of the respiratory tract. Staphylococcal infections—penicillin G-sensitive. Mild infections of the skin and soft tissues. Fusospirochetosis (Vincent's gingivitis and pharyngitis)—Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin.

Launch Date

1990
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
15 mg/L
1 g single, oral
dose: 1 g
route of administration: Oral
experiment type: SINGLE
co-administered:
PENICILLIN V POTASSIUM serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
26.3 mg/L
2 g single, oral
dose: 2 g
route of administration: Oral
experiment type: SINGLE
co-administered:
PENICILLIN V POTASSIUM serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
35.5 mg/L
3 g single, oral
dose: 3 g
route of administration: Oral
experiment type: SINGLE
co-administered:
PENICILLIN V POTASSIUM serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
6.1 mg/L
0.4 g single, oral
dose: 0.4 g
route of administration: Oral
experiment type: SINGLE
co-administered:
PENICILLIN V POTASSIUM serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
19.01 mg × h/L
1 g single, oral
dose: 1 g
route of administration: Oral
experiment type: SINGLE
co-administered:
PENICILLIN V POTASSIUM serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
33.36 mg × h/L
2 g single, oral
dose: 2 g
route of administration: Oral
experiment type: SINGLE
co-administered:
PENICILLIN V POTASSIUM serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
43.94 mg × h/L
3 g single, oral
dose: 3 g
route of administration: Oral
experiment type: SINGLE
co-administered:
PENICILLIN V POTASSIUM serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
6.89 mg × h/L
0.4 g single, oral
dose: 0.4 g
route of administration: Oral
experiment type: SINGLE
co-administered:
PENICILLIN V POTASSIUM serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
0.78 h
1 g single, oral
dose: 1 g
route of administration: Oral
experiment type: SINGLE
co-administered:
PENICILLIN V POTASSIUM serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
0.91 h
2 g single, oral
dose: 2 g
route of administration: Oral
experiment type: SINGLE
co-administered:
PENICILLIN V POTASSIUM serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1.05 h
3 g single, oral
dose: 3 g
route of administration: Oral
experiment type: SINGLE
co-administered:
PENICILLIN V POTASSIUM serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
0.52 h
0.4 g single, oral
dose: 0.4 g
route of administration: Oral
experiment type: SINGLE
co-administered:
PENICILLIN V POTASSIUM serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
20%
unknown, oral
PENICILLIN V POTASSIUM serum
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
10 mg/kg 4 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.48
unhealthy, 1-12
n = 216
Health Status: unhealthy
Condition: Streptococcal Pharyngitis
Age Group: 1-12
Sex: M+F
Population Size: 216
Sources: Page: p.48
Disc. AE: Stomach cramps, Nausea...
Other AEs: Diarrhea, Rash...
AEs leading to
discontinuation/dose reduction:
Stomach cramps (0.46%)
Nausea (0.46%)
Other AEs:
Diarrhea (0.8%)
Rash (1.2%)
Abdominal pain (0.8%)
Infection (1.7%)
Headache (1.2%)
Vomiting (2.5%)
Rhinitis (1.2%)
Gastroenteritis (0.4%)
Epistaxis (0.4%)
Ear pain (2.1%)
Cough increased (1.2%)
Nausea (0.8%)
Sources: Page: p.48
250 mg 4 times / day multiple, oral
Recommended
Dose: 250 mg, 4 times / day
Route: oral
Route: multiple
Dose: 250 mg, 4 times / day
Sources: Page: p.3A-25S
unhealthy, 16+
n = 117
Health Status: unhealthy
Condition: Streptococcal Pharyngitis
Age Group: 16+
Sex: M+F
Population Size: 117
Sources: Page: p.3A-25S
Disc. AE: Abdominal pain...
AEs leading to
discontinuation/dose reduction:
Abdominal pain (1.7%)
Sources: Page: p.3A-25S
590 mg 3 times / day multiple, oral
Recommended
Dose: 590 mg, 3 times / day
Route: oral
Route: multiple
Dose: 590 mg, 3 times / day
Sources: Page: p.341
unhealthy, 28+/-7.9
n = 113
Health Status: unhealthy
Condition: Streptococcal Pharyngitis
Age Group: 28+/-7.9
Sex: M+F
Population Size: 113
Sources: Page: p.341
Disc. AE: Nausea, Taste alteration...
AEs leading to
discontinuation/dose reduction:
Nausea (grade 3, 0.88%)
Taste alteration (grade 3, 0.88%)
Sources: Page: p.341
800 mg 4 times / day multiple, oral
Highest studied dose
Dose: 800 mg, 4 times / day
Route: oral
Route: multiple
Dose: 800 mg, 4 times / day
Sources:
unhealthy, 30.0 (6–73)
n = 212
Health Status: unhealthy
Condition: Pharyngotonsillitis caused by group A streptococci
Age Group: 30.0 (6–73)
Sex: M+F
Population Size: 212
Sources:
1 g 3 times / day multiple, oral
Recommended
Dose: 1 g, 3 times / day
Route: oral
Route: multiple
Dose: 1 g, 3 times / day
Sources:
unhealthy, 31.0 (3–67)
n = 210
Health Status: unhealthy
Condition: Pharyngotonsillitis caused by group A streptococci
Age Group: 31.0 (3–67)
Sex: M+F
Population Size: 210
Sources:
3 g multiple, oral
Recommended
Dose: 3 g
Route: oral
Route: multiple
Dose: 3 g
Sources: Page: p.2
unhealthy
Health Status: unhealthy
Condition: Prophylaxis against bacterial endocarditis
Sources: Page: p.2
250 mg 4 times / day multiple, oral
Recommended
Dose: 250 mg, 4 times / day
Route: oral
Route: multiple
Dose: 250 mg, 4 times / day
Sources: Page: p.70/306
unhealthy
n = 175
Health Status: unhealthy
Condition: Streptococcal pharyngitis|Streptococcal tonsillitis
Sex: M+F
Population Size: 175
Sources: Page: p.70/306
Disc. AE: Rash, Vomiting...
AEs leading to
discontinuation/dose reduction:
Rash (0.57%)
Vomiting (0.57%)
Sources: Page: p.70/306
500 mg 4 times / day multiple, oral (max)
Recommended
Dose: 500 mg, 4 times / day
Route: oral
Route: multiple
Dose: 500 mg, 4 times / day
Sources: Page: p.2
unhealthy
Health Status: unhealthy
Condition: Infections due to penicillin G­ sensitive microorganisms
Sources: Page: p.2
Disc. AE: Hypersensitivity reaction, Diarrhea, Clostridium difficile...
AEs leading to
discontinuation/dose reduction:
Hypersensitivity reaction (serious|grade 5)
Diarrhea, Clostridium difficile (mild|grade 5)
Sources: Page: p.2
AEs

AEs

AESignificanceDosePopulation
Epistaxis 0.4%
10 mg/kg 4 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.48
unhealthy, 1-12
n = 216
Health Status: unhealthy
Condition: Streptococcal Pharyngitis
Age Group: 1-12
Sex: M+F
Population Size: 216
Sources: Page: p.48
Gastroenteritis 0.4%
10 mg/kg 4 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.48
unhealthy, 1-12
n = 216
Health Status: unhealthy
Condition: Streptococcal Pharyngitis
Age Group: 1-12
Sex: M+F
Population Size: 216
Sources: Page: p.48
Nausea 0.46%
Disc. AE
10 mg/kg 4 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.48
unhealthy, 1-12
n = 216
Health Status: unhealthy
Condition: Streptococcal Pharyngitis
Age Group: 1-12
Sex: M+F
Population Size: 216
Sources: Page: p.48
Stomach cramps 0.46%
Disc. AE
10 mg/kg 4 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.48
unhealthy, 1-12
n = 216
Health Status: unhealthy
Condition: Streptococcal Pharyngitis
Age Group: 1-12
Sex: M+F
Population Size: 216
Sources: Page: p.48
Abdominal pain 0.8%
10 mg/kg 4 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.48
unhealthy, 1-12
n = 216
Health Status: unhealthy
Condition: Streptococcal Pharyngitis
Age Group: 1-12
Sex: M+F
Population Size: 216
Sources: Page: p.48
Diarrhea 0.8%
10 mg/kg 4 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.48
unhealthy, 1-12
n = 216
Health Status: unhealthy
Condition: Streptococcal Pharyngitis
Age Group: 1-12
Sex: M+F
Population Size: 216
Sources: Page: p.48
Nausea 0.8%
10 mg/kg 4 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.48
unhealthy, 1-12
n = 216
Health Status: unhealthy
Condition: Streptococcal Pharyngitis
Age Group: 1-12
Sex: M+F
Population Size: 216
Sources: Page: p.48
Cough increased 1.2%
10 mg/kg 4 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.48
unhealthy, 1-12
n = 216
Health Status: unhealthy
Condition: Streptococcal Pharyngitis
Age Group: 1-12
Sex: M+F
Population Size: 216
Sources: Page: p.48
Headache 1.2%
10 mg/kg 4 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.48
unhealthy, 1-12
n = 216
Health Status: unhealthy
Condition: Streptococcal Pharyngitis
Age Group: 1-12
Sex: M+F
Population Size: 216
Sources: Page: p.48
Rash 1.2%
10 mg/kg 4 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.48
unhealthy, 1-12
n = 216
Health Status: unhealthy
Condition: Streptococcal Pharyngitis
Age Group: 1-12
Sex: M+F
Population Size: 216
Sources: Page: p.48
Rhinitis 1.2%
10 mg/kg 4 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.48
unhealthy, 1-12
n = 216
Health Status: unhealthy
Condition: Streptococcal Pharyngitis
Age Group: 1-12
Sex: M+F
Population Size: 216
Sources: Page: p.48
Infection 1.7%
10 mg/kg 4 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.48
unhealthy, 1-12
n = 216
Health Status: unhealthy
Condition: Streptococcal Pharyngitis
Age Group: 1-12
Sex: M+F
Population Size: 216
Sources: Page: p.48
Ear pain 2.1%
10 mg/kg 4 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.48
unhealthy, 1-12
n = 216
Health Status: unhealthy
Condition: Streptococcal Pharyngitis
Age Group: 1-12
Sex: M+F
Population Size: 216
Sources: Page: p.48
Vomiting 2.5%
10 mg/kg 4 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.48
unhealthy, 1-12
n = 216
Health Status: unhealthy
Condition: Streptococcal Pharyngitis
Age Group: 1-12
Sex: M+F
Population Size: 216
Sources: Page: p.48
Abdominal pain 1.7%
Disc. AE
250 mg 4 times / day multiple, oral
Recommended
Dose: 250 mg, 4 times / day
Route: oral
Route: multiple
Dose: 250 mg, 4 times / day
Sources: Page: p.3A-25S
unhealthy, 16+
n = 117
Health Status: unhealthy
Condition: Streptococcal Pharyngitis
Age Group: 16+
Sex: M+F
Population Size: 117
Sources: Page: p.3A-25S
Nausea grade 3, 0.88%
Disc. AE
590 mg 3 times / day multiple, oral
Recommended
Dose: 590 mg, 3 times / day
Route: oral
Route: multiple
Dose: 590 mg, 3 times / day
Sources: Page: p.341
unhealthy, 28+/-7.9
n = 113
Health Status: unhealthy
Condition: Streptococcal Pharyngitis
Age Group: 28+/-7.9
Sex: M+F
Population Size: 113
Sources: Page: p.341
Taste alteration grade 3, 0.88%
Disc. AE
590 mg 3 times / day multiple, oral
Recommended
Dose: 590 mg, 3 times / day
Route: oral
Route: multiple
Dose: 590 mg, 3 times / day
Sources: Page: p.341
unhealthy, 28+/-7.9
n = 113
Health Status: unhealthy
Condition: Streptococcal Pharyngitis
Age Group: 28+/-7.9
Sex: M+F
Population Size: 113
Sources: Page: p.341
Rash 0.57%
Disc. AE
250 mg 4 times / day multiple, oral
Recommended
Dose: 250 mg, 4 times / day
Route: oral
Route: multiple
Dose: 250 mg, 4 times / day
Sources: Page: p.70/306
unhealthy
n = 175
Health Status: unhealthy
Condition: Streptococcal pharyngitis|Streptococcal tonsillitis
Sex: M+F
Population Size: 175
Sources: Page: p.70/306
Vomiting 0.57%
Disc. AE
250 mg 4 times / day multiple, oral
Recommended
Dose: 250 mg, 4 times / day
Route: oral
Route: multiple
Dose: 250 mg, 4 times / day
Sources: Page: p.70/306
unhealthy
n = 175
Health Status: unhealthy
Condition: Streptococcal pharyngitis|Streptococcal tonsillitis
Sex: M+F
Population Size: 175
Sources: Page: p.70/306
Diarrhea, Clostridium difficile mild|grade 5
Disc. AE
500 mg 4 times / day multiple, oral (max)
Recommended
Dose: 500 mg, 4 times / day
Route: oral
Route: multiple
Dose: 500 mg, 4 times / day
Sources: Page: p.2
unhealthy
Health Status: unhealthy
Condition: Infections due to penicillin G­ sensitive microorganisms
Sources: Page: p.2
Hypersensitivity reaction serious|grade 5
Disc. AE
500 mg 4 times / day multiple, oral (max)
Recommended
Dose: 500 mg, 4 times / day
Route: oral
Route: multiple
Dose: 500 mg, 4 times / day
Sources: Page: p.2
unhealthy
Health Status: unhealthy
Condition: Infections due to penicillin G­ sensitive microorganisms
Sources: Page: p.2
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Unusual evidence of myocardial involvement during a hypersensitivity reaction to oral penicillin.
1978 Aug
Identification of penicillin allergenic determinants that bind IgE antibodies in the sera of subjects with penicillin allergy.
1990 Nov
Antibacterial drugs prescribed for dogs and cats in Sweden and Norway 1990-1998.
2001
Biphasic illness pattern due to early relapse in Japanese-B virus encephalitis.
2001 Jan 15
Effect of recolonisation with "interfering" alpha streptococci on recurrences of acute and secretory otitis media in children: randomised placebo controlled trial.
2001 Jan 27
Antibiotic prescribing in general practice: striking differences between Italy (Ravenna) and Denmark (Funen).
2002 Dec
Solitary borrelial lymphocytoma in adult patients.
2002 Jul 31
Solitary erythema migrans in children: comparison of treatment with azithromycin and phenoxymethylpenicillin.
2002 Jul 31
Liquid chromatographic determination of ampicillin residues in porcine muscle tissue by a multipenicillin analytical method: European Collaborative Study.
2002 Jul-Aug
[Impact of regulatory measures in the trends of community consumption of antibiotics in Chile].
2002 Nov
beta-Lactam allergenic determinants: fine structural recognition of a cross-reacting determinant on benzylpenicillin and cephalothin.
2002 Nov
Clinical outcome of erythema migrans after treatment with phenoxymethyl penicillin.
2003
Telithromycin: new preparation. A needless addition to the other macrolides.
2003 Feb
Fast separations on monolithic silica columns: method transfer, robustness and column ageing for some case studies.
2003 Jun 1
Reoccurrence of levofloxacin-induced tendinitis by phenoxymethylpenicillin therapy after 6 months: a rare complication of fluoroquinolone therapy?
2003 May
Recurrent pneumococcal meningitis in a splenectomised HIV-infected patient.
2003 Nov 7
Antibiotics for acute group A streptococcal pharyngitis.
2004 Dec
Specific serum IgE levels and FcepsilonRIbeta genetic polymorphism in patients with penicillins allergy.
2004 Dec
[Bite wound infections].
2004 Dec 16
Limited spread of penicillin-nonsusceptible pneumococci, Skåne County, Sweden.
2004 Jun
[Prevention and infection in adults patients with hyposplenism].
2004 Nov
Penicillin V, loracarbef and clindamycin in tonsillar surface fluid during acute group A streptococcal pharyngotonsillitis.
2005
Antigen specific quantification of sulfidoleukotrienes in patients allergic to Betalactam antibiotics.
2005
Relationships between skin test, specific IgE and levels of cytokines in patients with penicillin allergy.
2005 Aug
Differential effects of beta-lactams on human IFN-gamma activity.
2005 Dec
Inadvertent use of Bicillin C-R to treat syphilis infection--Los Angeles, California, 1999-2004.
2005 Mar 11
Clinical practice. Antibiotic allergy.
2006 Feb 9
Facilitated column selection in pharmaceutical analyses using a simple column classification system.
2006 Jan 6
HLA-DRB genotype and specific IgE responses in patients with allergies to penicillins.
2006 Mar 20
[The microbiology of peritonsillar abscesses].
2007
Hypersensitivity to penicillin V with good tolerance to other beta-lactams.
2007
Meningomylocele: An update.
2007 Apr
Aminopenicillin-induced exanthema allows treatment with certain cephalosporins or phenoxymethyl penicillin.
2007 Jul
Dishing the dirt on asthma: What we can learn from poor hygiene.
2007 Jun
Incidence of antibiotic prescribing in dental practice in Norway and its contribution to national consumption.
2007 Jun
Evaluation of phenoxymethylpenicillin treatment of acute otitis media in children aged 2-16.
2007 Sep
A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine.
2008 Aug
Antimicrobial susceptibility of periodontopathogenic bacteria.
2008 May
Drug use in children: cohort study in three European countries.
2008 Nov 24
Antistreptococcal treatment of guttate psoriasis: a controlled study.
2008 Sep
Treatment of Lyme borreliosis.
2009
Comparative Study of 5-Day and 10-Day Cefditoren Pivoxil Treatments for Recurrent Group A beta-Hemolytic Streptococcus pharyngitis in Children.
2009
SDRIFE (baboon syndrome) induced by penicillin.
2009 Apr
Challenges of cellulitis in a lymphedematous extremity: a case report.
2009 Dec 22
[An exceptional component C3 deficiency revealed by serum protein electrophoresis].
2009 Nov-Dec
Human health risk assessment of pharmaceuticals in water: issues and challenges ahead.
2010 Nov
Prevalence of Group A b-Hemolytic Streptococcus Among Children with Tonsillopharyngitis in Kyrgyzstan: The Difficulty of Diagnostics and Therapy.
2010 Oct 13
Patents

Sample Use Guides

Usual Adult Dose for Bacterial Infection Mild to moderate infections: 125 to 500 mg orally every 6 to 8 hours
Route of Administration: Oral
Penicillin V inhibited Staphylococcus aureus in human THP-1 macrophages (intracellular) with MIC90 of 0.015 mg/L
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:03:29 GMT 2023
Edited
by admin
on Fri Dec 15 16:03:29 GMT 2023
Record UNII
146T0TU1JB
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PENICILLIN V POTASSIUM
GREEN BOOK   HSDB   ORANGE BOOK   USAN   USP   USP-RS   VANDF  
USAN  
Official Name English
PENICILLIN V POTASSIUM [HSDB]
Common Name English
PENICILLIN PHENOXYMETHYL POTASSIUM
Common Name English
Monopotassium (2S,5R,6R)-3,3-dimethyl-7-oxo-6-(2-phenoxyacetamido)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
Systematic Name English
ANTIBIOCIN
Common Name English
PHENOXYMETHYLPENICILLIN POTASSIUM [EP MONOGRAPH]
Common Name English
4-THIA-1-AZABICYCLO(3.2.0)HEPTANE-2-CARBOXYLIC ACID, 3,3-DIMETHYL-7-OXO-6-((PHENOXYACETYL)AMINO)-, MONOPOTASSIUM SALT, (2S-(2.ALPHA.,5.ALPHA.,6.BETA.))-
Common Name English
PENICILLIN V POTASSIUM [USAN]
Common Name English
PRIMCILLIN
Common Name English
PENICILLIN POTASSIUM PHENOXYMETHYL
Common Name English
POTASSIUM PENICILLIN V
Common Name English
PENICILLIN VK
Brand Name English
PENAPAR-VK
Brand Name English
V-CILLIN K
Brand Name English
PENICILLIN V POTASSIUM [ORANGE BOOK]
Common Name English
PENICILLIN V POTASSIUM [USP-RS]
Common Name English
PENICILLIN V POTASSIUM [USP MONOGRAPH]
Common Name English
LEDERCILLIN VK
Brand Name English
NSC-757258
Code English
PHENOXYMETHYLPENICILLIN POTASSIUM [MART.]
Common Name English
Phenoxymethylpenicillin potassium [WHO-DD]
Common Name English
PHENOXYMETHYLPENICILLIN POTASSIUM [WHO-IP]
Common Name English
PHENOXYMETHYLPENICILLIN POTASSIUM
EP   JAN   MART.   WHO-DD   WHO-IP  
Common Name English
BEEPEN-VK
Brand Name English
PEN-VEE K
Brand Name English
UTICILLIN VK
Brand Name English
PENICILLIN V POTASSIUM [USP IMPURITY]
Common Name English
PFIZERPEN VK
Brand Name English
PENICILLIN V POTASSIUM SALT
MI  
Common Name English
PHENOXYMETHYLPENICILLIN POTASSIUM [JAN]
Common Name English
PENICILLIN V POTASSIUM [GREEN BOOK]
Common Name English
VAMOSYN
Common Name English
PENICILLIN V POTASSIUM [VANDF]
Common Name English
VEETIDS
Brand Name English
BETAPEN-VK
Brand Name English
PHENOXYMETHYLPENICILLINUM KALICUM [WHO-IP LATIN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C1500
Created by admin on Fri Dec 15 16:03:30 GMT 2023 , Edited by admin on Fri Dec 15 16:03:30 GMT 2023
Code System Code Type Description
CAS
132-98-9
Created by admin on Fri Dec 15 16:03:30 GMT 2023 , Edited by admin on Fri Dec 15 16:03:30 GMT 2023
PRIMARY
MERCK INDEX
m8479
Created by admin on Fri Dec 15 16:03:30 GMT 2023 , Edited by admin on Fri Dec 15 16:03:30 GMT 2023
PRIMARY Merck Index
FDA UNII
146T0TU1JB
Created by admin on Fri Dec 15 16:03:30 GMT 2023 , Edited by admin on Fri Dec 15 16:03:30 GMT 2023
PRIMARY
CHEBI
7967
Created by admin on Fri Dec 15 16:03:30 GMT 2023 , Edited by admin on Fri Dec 15 16:03:30 GMT 2023
PRIMARY
RXCUI
203195
Created by admin on Fri Dec 15 16:03:30 GMT 2023 , Edited by admin on Fri Dec 15 16:03:30 GMT 2023
PRIMARY RxNorm
RS_ITEM_NUM
1504503
Created by admin on Fri Dec 15 16:03:30 GMT 2023 , Edited by admin on Fri Dec 15 16:03:30 GMT 2023
PRIMARY
HSDB
6315
Created by admin on Fri Dec 15 16:03:30 GMT 2023 , Edited by admin on Fri Dec 15 16:03:30 GMT 2023
PRIMARY
DRUG BANK
DBSALT000299
Created by admin on Fri Dec 15 16:03:30 GMT 2023 , Edited by admin on Fri Dec 15 16:03:30 GMT 2023
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
PENICILLIN V POTASSIUM
Created by admin on Fri Dec 15 16:03:30 GMT 2023 , Edited by admin on Fri Dec 15 16:03:30 GMT 2023
PRIMARY Description: A white or almost white, crystalline powder; odourless or with a faint characteristic odour. Solubility: Soluble in about 1.5 parts of water; practically insoluble in ether R. Category: Antibiotic. Storage: Phenoxymethylpenicillin potassium should be kept in a tightly closed container; protected from light. Additional information: Even in the absence of light, Phenoxymethylpenicillin potassium is gradually degraded on exposure to ahumid atmosphere, the decomposition being faster at higher temperatures. Definition: Phenoxymethylpenicillin potassium contains not less than 95.0% and not more than 102.0% of C16H17KN2O5S,calculated with reference to the dried substance.
EVMPD
SUB03766MIG
Created by admin on Fri Dec 15 16:03:30 GMT 2023 , Edited by admin on Fri Dec 15 16:03:30 GMT 2023
PRIMARY
SMS_ID
100000090273
Created by admin on Fri Dec 15 16:03:30 GMT 2023 , Edited by admin on Fri Dec 15 16:03:30 GMT 2023
PRIMARY
NSC
757258
Created by admin on Fri Dec 15 16:03:30 GMT 2023 , Edited by admin on Fri Dec 15 16:03:30 GMT 2023
PRIMARY
NCI_THESAURUS
C730
Created by admin on Fri Dec 15 16:03:30 GMT 2023 , Edited by admin on Fri Dec 15 16:03:30 GMT 2023
PRIMARY
DAILYMED
146T0TU1JB
Created by admin on Fri Dec 15 16:03:30 GMT 2023 , Edited by admin on Fri Dec 15 16:03:30 GMT 2023
PRIMARY
ECHA (EC/EINECS)
205-086-5
Created by admin on Fri Dec 15 16:03:30 GMT 2023 , Edited by admin on Fri Dec 15 16:03:30 GMT 2023
PRIMARY
EPA CompTox
DTXSID7021102
Created by admin on Fri Dec 15 16:03:30 GMT 2023 , Edited by admin on Fri Dec 15 16:03:30 GMT 2023
PRIMARY
PUBCHEM
23676814
Created by admin on Fri Dec 15 16:03:30 GMT 2023 , Edited by admin on Fri Dec 15 16:03:30 GMT 2023
PRIMARY
ChEMBL
CHEMBL615
Created by admin on Fri Dec 15 16:03:30 GMT 2023 , Edited by admin on Fri Dec 15 16:03:30 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC Elimination
PHARMACOKINETIC